Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the PEACE-1 and STAMPEDE (NCT00268476) trials, both presented at this year's European Society for Medical Oncology (ESMO) 2021 congress. The first study discussed is the STAMPEDE trial is a randomized, controlled trial recruiting in the UK and Switzerland that aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-naïve prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control arm. The second study discussed, PEACE-1 (NCT01957436) is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patients with metastatic hormone-naïve prostate cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
- Prostate cancer updates at ESMO 2021: STAMPEDE and PEACE-1 ( Download)
- Practice-changing data from ESMO 2021 in prostate cancer ( Download)
- Clinical trial updates in prostate cancer at ESMO 2022 ( Download)
- Prostate and bladder highlights at ESMO 2021 ( Download)
- ESMO 2021: Updates in hormone-sensitive prostate cancer ( Download)
- PEACE-1 trial ( Download)
- #ESMO21 Highlights on MFS analysis from comb. treatments in high-risk adv. prostate cancer: STAMPEDE ( Download)
- Prostate Cancer Highlights from ESMO 2022 ( Download)
- Highlights in prostate cancer from ESMO ( Download)
- #ESMO21 Expert Video Report on Prostate cancer ( Download)
- Expert Video Report on castration sensitive and resistant prostate cancer - 2021 ASCO Annual Meeting ( Download)
- Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216 ( Download)
- Expert video report on Prostate Cancer from 2021 Genitourinary Cancers Symposium ( Download)
- Recent updates in prostate cancer: STAMPEDE, VISION & PROfound ( Download)
- PEACE-1: 8-month PSA determines outcomes in men with mCSPC ( Download)
